3.58
price up icon1.13%   0.04
after-market Dopo l'orario di chiusura: 3.47 -0.11 -3.07%
loading

Maxcyte Inc Borsa (MXCT) Ultime notizie

pulisher
08:23 AM

MaxCyte to Participate in Two Upcoming Investor Conferences - StockTitan

08:23 AM
pulisher
08:17 AM

MaxCyte to Join Key Investor Conferences in November - TipRanks

08:17 AM
pulisher
03:58 AM

MaxCyte’s Insider Stock Activity in Focus - TipRanks

03:58 AM
pulisher
Oct 30, 2024

MaxCyte director Johnston sells $11,166 in stock - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday - MarketBeat

Oct 30, 2024
pulisher
Oct 18, 2024

Grant of Options and Restricted Stock Units - ShareCast

Oct 18, 2024
pulisher
Oct 18, 2024

MaxCyte Awards Stock Options to Boost Growth - TipRanks

Oct 18, 2024
pulisher
Oct 16, 2024

MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

Oct 16, 2024
pulisher
Oct 15, 2024

MaxCyte Appoints Cynthia Collins to its Board of Directors - ForexTV.com

Oct 15, 2024
pulisher
Oct 15, 2024

MaxCyte Strengthens Board with Cynthia Collins Appointment - TipRanks

Oct 15, 2024
pulisher
Oct 15, 2024

MaxCyte adds biotech veteran Collins to board - Investing.com

Oct 15, 2024
pulisher
Oct 12, 2024

MaxCyte appoints Ali Soleymannezhad as Chief Commercial Officer - Head Topics

Oct 12, 2024
pulisher
Oct 11, 2024

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 - ForexTV.com

Oct 11, 2024
pulisher
Oct 11, 2024

MaxCyte to Unveil Q3 2024 Financial Results - TipRanks

Oct 11, 2024
pulisher
Oct 10, 2024

People on the Move: Ali Soleymannezhad, Chief Commercial Officer, MaxCyte - BioBuzz

Oct 10, 2024
pulisher
Oct 10, 2024

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer - citybiz

Oct 10, 2024
pulisher
Oct 10, 2024

MaxCyte appoints new chief commercial officer - ShareCast

Oct 10, 2024
pulisher
Oct 10, 2024

MaxCyte appoints Soleymannezhad as CCO - TipRanks

Oct 10, 2024
pulisher
Oct 10, 2024

MaxCyte Names New CCO for Market Expansion - TipRanks

Oct 10, 2024
pulisher
Oct 10, 2024

MaxCyte upgraded to Buy from Hold at Deutsche Bank - TipRanks

Oct 10, 2024
pulisher
Oct 05, 2024

Marshall Wace LLP Acquires New Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up (NASDAQ:MXCT) - Seeking Alpha

Oct 04, 2024
pulisher
Oct 03, 2024

Stan Erck Sells 47,689 Shares of MaxCyte, Inc. (LON:MXCT) Stock - MarketBeat

Oct 03, 2024
pulisher
Oct 03, 2024

MaxCyte, Inc. (LON:MXCT) Insider Sells £185,033.32 in Stock - Defense World

Oct 03, 2024
pulisher
Oct 03, 2024

MaxCyte Director Executes Stock Options Sale - TipRanks

Oct 03, 2024
pulisher
Oct 02, 2024

MaxCyte director Stanley Erck sells shares worth over $178k - Investing.com

Oct 02, 2024
pulisher
Oct 02, 2024

MaxCyte director Stanley Erck sells shares worth over $178k By Investing.com - Investing.com Australia

Oct 02, 2024
pulisher
Oct 02, 2024

MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $80,161.97 in Stock - MarketBeat

Oct 02, 2024
pulisher
Oct 02, 2024

Overcome the limitations of conventional transfection with MaxCyte Electroporation - LabRoots

Oct 02, 2024
pulisher
Oct 01, 2024

MaxCyte Director Executes Stock Options and Sells Shares - TipRanks

Oct 01, 2024
pulisher
Oct 01, 2024

MaxCyte Expands Share Capital, Fuels Cell Therapy Growth - TipRanks

Oct 01, 2024
pulisher
Sep 30, 2024

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares - Defense World

Sep 30, 2024
pulisher
Sep 30, 2024

Maxcyte director Johnston sells shares worth over $11,000 By Investing.com - Investing.com Australia

Sep 30, 2024
pulisher
Sep 30, 2024

Maxcyte director Johnston sells shares worth over $11,000 - Investing.com

Sep 30, 2024
pulisher
Sep 27, 2024

BlackRock Adjusts Stake in MaxCyte, Inc. - TipRanks

Sep 27, 2024
pulisher
Sep 27, 2024

BlackRock Increases Stake in MaxCyte, Inc. - TipRanks

Sep 27, 2024
pulisher
Sep 26, 2024

MaxCyte (LON:MXCT) Stock Price Passes Below 50 Day Moving Average of $325.72 - MarketBeat

Sep 26, 2024
pulisher
Sep 26, 2024

MaxCyte (LON:MXCT) Shares Cross Below 50 Day Moving Average of $325.72 - Defense World

Sep 26, 2024
pulisher
Sep 25, 2024

MaxCyte shares retain buy rating on strong cell therapy platform By Investing.com - Investing.com Australia

Sep 25, 2024
pulisher
Sep 24, 2024

MaxCyte shares retain buy rating on strong cell therapy platform - Investing.com

Sep 24, 2024
pulisher
Sep 24, 2024

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth - Yahoo Finance

Sep 24, 2024
pulisher
Sep 24, 2024

Massachusetts Financial Services Co. MA Has $1.96 Million Stake in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases - MSN

Sep 23, 2024
pulisher
Sep 23, 2024

Massachusetts Financial Services Co. MA Cuts Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World

Sep 23, 2024
pulisher
Sep 20, 2024

BlackRock Ups Stake in MaxCyte to 9.75% - TipRanks

Sep 20, 2024
pulisher
Sep 20, 2024

Rx Rundown: MaxCyte, Roche, and more - MM+M Online

Sep 20, 2024
pulisher
Sep 19, 2024

MaxCyte Signs Strategic Platform License With Kamau Therapeutics To Accelerate the Development of Cell Therapies for Genetic Diseases - Technology Networks

Sep 19, 2024
pulisher
Sep 19, 2024

Bank of New York Mellon Corp Has $1.66 Million Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World

Sep 19, 2024
pulisher
Sep 17, 2024

MaxCyte and Kamau Therapeutics sign platform license agreement - Pharmaceutical Technology

Sep 17, 2024
medical_devices STE
$221.85
price down icon 1.13%
medical_devices ZBH
$106.92
price down icon 2.63%
medical_devices PHG
$26.20
price down icon 0.46%
$70.48
price down icon 1.84%
$87.35
price up icon 0.17%
medical_devices EW
$67.01
price down icon 2.36%
Capitalizzazione:     |  Volume (24 ore):